type of report	**Current report**
number	7/2015
company	PHARMENA

Determining the date of assessment concerning the completion of application for authorisation of 1-MNA dietary supplement

With reference to the Company's Strategy for 2012-2015 (published in current report No. 16/2012 of 13.04.2012) and the information on completing the application for authorisation of 1-MNA as a new food ingredient (published in curent report No. 55/2014 of 06.11.2014) the Management Board of PHARMENA S.A. informs that according to the information published on the website of the Food Standards Agency (FSA) in London submitted documents completing the application for authorisation of a new food ingredient pursuant to Art. 4 of the Regulation (EC) No. 258/97 are going to be evaluated during the next session of the Advisory Committee on Novel Foods and Processes (ACNFP), which is scheduled for 12th February this year. The Issuer shall inform about the result of the assessment concerning the authorisation of the 1-MNA dietary supplement in a separate current report.

The procedure stipulated in provisions of Art. 4 of Regulation (EC) no. 258/97 of the European Parliament and of the Council of 27th January 1997, concerns foods and food ingredients that have no record of safe consumption in the Community, which means they were not used in foods before 15th May 1997 in any EU Member State. The goal of subjecting 1-MNA to this procedure is to prove, basing on research and scientific publications that are available for PHARMENA S.A., the safety of the ingredient's use within the proposed area. Within this procedure, the entity responsible for placing the new food ingredient on the Community market submits appropriate application to the EU Member State, where the new foodstuff is to be first placed on the market. An additional scientific assessment at European level may appear necessary. In such case, it will be performed by European Food Safety Authority (EFSA). Following full assessment, the European Commission grants permission for placing the new foodstuff on the market.

Successful authorisation will open EU markets for the dietary supplement.

The 1-MNA dietary supplement will be an innovative product with a capacity to influence risk biomarkers of cardiovascular diseases and to stimulate the endogenous (natural) production of prostacyclin. Low levels of prostacyclin in human organism increase the risk of atherosclerosis. Studies have shown that the concentration of endogenous 1-MNA in human organism decreases with age. 1-MNA dietary supplement can complement 1-MNA deficiency in the organism and therefore stimulate the production of prostacyclin, which reduces the risk of developing atherosclerosis.

The information is made public due to the fact that the introduction of innovative dietary supplement containing 1-MNA on the market may have a significant influence on the Company's revenue during the next several years.

Legal basis:

Alternative Trading System Rules – Exhibit 3 "Current and Periodical Information in the Alternative Trading System on the NewConnect Market", Article 3 (1).